TEVA Rallies on S&P Credit Upgrade, $40 Price Target Hike, and Fresh Pipeline Catalysts
Teva Pharmaceutical Industries Limited (NYSE: TEVA; TASE: TEVA) stock is finishing 2025 with unusual momentum for a company long labeled “just a generics maker.” On Dec. 24, 2025, TEVA is trading around the $31–$32 range after a sharp run-up over the past several weeks, with holiday-thinned markets now digesting a cluster of developments that bulls say strengthen Teva’s “pivot to growth” story—and bears say risk turning into a valuation trap. [1]
This is the key backdrop: credit conditions are improving, analysts are lifting targets, and Teva’s pipeline/biosimilars calendar is getting clearer—all while the company is still navigating the industry’s classic landmines (pricing pressure, patent cliffs, and litigation).
